ew alternative therapeutical strategies in early senescence and immunosenescence

Phase 3

Recruiting

• Conditions: Mild cognitive impairment; Immunosenescence; Mental Health - Studies of normal psychology, cognitive function and behaviour; Inflammatory and Immune System - Normal development and function of the immune system

• Registration Number: ACTRN12612001159842
• Lead Sponsor: niversity of Medicine and Pharmacy Victor Babes Timisoara

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-11-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

Subjects with 65 years of age and older than 65;
Subjects diagnosed with MCI (MMSE score =21-28 points).

Exclusion Criteria

Subjects younger than 65 years;
Subjects with MCI due to major depressive disorder and schizophrenia;
Subjects with moderate and severe cognitive impairment (MMSE score under 21 points).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mild cognitive impairment improvement, as assessed by MMSE, clock, and Raven tests.[Initial screening, first assessment at 6 months, second assessment at one year.]

Secondary Outcome Measures

Name	Time	Method
Immunosenescence improvement, as assessed byimmune phenotype of peripheral blood CD8+ T cells.[Initial screening, and assessment at one year.]